# Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults

> **NCT03437304** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eurocine Vaccines AB** · enrollment: 298 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Immunose™ FLU 1%
- **BIOLOGICAL:** Immunose™ FLU 2%, 200 μl
- **BIOLOGICAL:** Immunose™ FLU 2%, 300 μl
- **BIOLOGICAL:** Influenza antigen
- **DRUG:** Placebo
- **BIOLOGICAL:** i.m comparator

## Key facts

- **NCT ID:** NCT03437304
- **Lead sponsor:** Eurocine Vaccines AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-09
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437304, "Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03437304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*